Streetbeat News

Earnings

AYX

Alteryx reported Q2 losses of $(0.37) per share, beating the analyst consensus estimate of $(0.66) by 43.94%. This is a 19.57% increase over losses from the same period last year. The company also reported quarterly sales of $188.00 million, beating the analyst consensus estimate of $182.15 million by 3.21%. This is a 4.08% increase over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 8:40 pm

JRVR

James River Gr Hldgs (NASDAQ:JRVR) reported Q2 earnings of $0.53 per share, beating the analyst consensus estimate of $0.49 by 8.16%. However, the company's quarterly sales of $209.66 million missed the analyst consensus estimate of $214.70 million by 2.35%. This represents a 1.92% increase in earnings and a 12.56% increase in sales compared to the same period last year.

Portfolio Pulse from mahesh@benzinga.com

August 07, 2023 | 8:40 pm

FORG

ForgeRock (NYSE:FORG) reported Q2 losses of $(0.15) per share, an 11.76% improvement from $(0.17) per share YoY. Sales for the quarter were $58.28M, a 22.25% increase from $47.68M YoY.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 8:40 pm

DCGO

DocGo (NASDAQ:DCGO) reported Q2 earnings per share of $(0.02), missing the analyst consensus estimate of $0.03 by 166.67%. This is a 118.18% decrease from the same period last year. However, the company's quarterly sales of $125.49 million beat the analyst consensus estimate of $119.64 million by 4.89%, marking a 14.58% increase from the same period last year.

Portfolio Pulse from sunil@benzinga.com

August 07, 2023 | 8:39 pm

TBPH

Theravance Biopharma reported Q2 losses of $0.28 per share, missing the analyst consensus estimate of $0.16 by 75%. This is a 600% increase in losses from the same period last year. The company also reported quarterly sales of $13.75 million, missing the analyst consensus estimate of $15.24 million by 9.78%. However, this is a 24.43% increase in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 8:39 pm

VECO

Veeco Instruments Inc. has projected its Q3 earnings per share (EPS) to be between $0.30 and $0.40, compared to the estimated $0.33. The company also expects its Q3 revenue to be between $155M and $175M, against the estimated $168.26M.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 8:39 pm

RC

Ready Capital (NYSE:RC) reported Q2 earnings of $0.35 per share, missing the analyst consensus estimate of $0.36 by 2.78%. This is a 23.91% decrease from the same period last year. The company also reported quarterly sales of $60.35 million, missing the analyst consensus estimate of $62.72 million by 3.78%. This is a 17.15% decrease from the same period last year.

Portfolio Pulse from bharat@benzinga.com

August 07, 2023 | 8:39 pm

MED

Medifast has projected its Q3 revenue to be between $220M and $240M, with an EPS of $0.71 to $1.32.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 8:39 pm

SIBN

SI-BONE (NASDAQ:SIBN) reported Q2 losses of $(0.30) per share, beating the analyst consensus estimate of $(0.41) by 26.83%. This is a 44.44% increase over losses from the same period last year. The company also reported quarterly sales of $33.30 million, beating the analyst consensus estimate of $32.24 million by 3.29%. This is a 30.15% increase over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 8:37 pm

MRVI

Maravai LifeSciences reported Q2 sales of $68.91 million, missing the analyst consensus estimate of $70.30 million by 1.97 percent. This represents a 71.61 percent decrease from the same period last year.

Portfolio Pulse from sunil@benzinga.com

August 07, 2023 | 8:36 pm